On May 1, 2024 Alkermes plc (Nasdaq: ALKS) reported financial results for the first quarter of 2024 (Press release, Alkermes, MAY 1, 2024, View Source [SID1234642503]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company. During the quarter, we continued to advance our strategic priorities across the business, highlighted by solid underlying prescription growth for LYBALVI and advancement of ALKS 2680, our novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy," said Richard Pops, Chief Executive Officer of Alkermes. "For ALKS 2680, we recently initiated our Vibrance-1 phase 2 study in narcolepsy type 1 and announced positive topline phase 1b results in narcolepsy type 2. With these new data now in hand, we plan to initiate a phase 2 study in narcolepsy type 2 in the second half of 2024. In an area where there remains significant unmet patient need, orexin 2 biology represents an important new potential approach to treating disorders characterized by excessive daytime sleepiness. ALKS 2680 is the first candidate from our orexin portfolio to advance in the clinic and we plan to share details regarding our other orexin development programs later this year."
Key Financial Highlights
Revenues
(In millions)
Three Months Ended
March 31,
2024
2023
Total Revenues
$
350.4
$
287.6
Total Proprietary Net Sales
$
233.5
$
214.7
VIVITROL
$
97.7
$
96.7
ARISTADAi
$
78.9
$
80.1
LYBALVI
$
57.0
$
38.0
Profitability
(In millions)
Three Months Ended
March 31,
2024
2023
GAAP Net Income (Loss) From Continuing Operations
$
38.9
$
(12.1)
GAAP Net Loss From Discontinued Operations
$
(2.1)
$
(29.8)
GAAP Net Income (Loss)
$
36.8
$
(41.8)
Non-GAAP Net Income From Continuing Operations
$
76.2
$
30.1
Non-GAAP Net Loss From Discontinued Operations
$
(2.1)
$
(27.6)
Non-GAAP Net Income
$
74.1
$
2.4
EBITDA From Continuing Operations
$
51.5
$
7.2
EBITDA From Discontinued Operations
$
(2.5)
$
(36.0)
EBITDA
$
49.0
$
(28.8)
Revenue Highlights
LYBALVI
Revenues for the quarter were $57.0 million.
Revenues and total prescriptions for the quarter grew 50% and 56%, respectively, compared to the first quarter of 2023.
Inventory in the channel decreased by approximately $2.3 million during the quarter.
ARISTADAi
Revenues for the quarter were $78.9 million.
Inventory in the channel decreased by approximately $3.6 million during the quarter.
VIVITROL
Revenues for the quarter were $97.7 million.
Inventory in the channel decreased by approximately $4.3 million during the quarter.
Manufacturing & Royalty Revenues
Royalty revenues from INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANNLI for the quarter were $62.7 million.
VUMERITY manufacturing and royalty revenues for the quarter were $31.3 million.
Key Operating Expenses
Please see Note 1 below for details regarding discontinued operations.
(In millions)
Three Months Ended
March 31,
2024
2023
R&D Expense – Continuing Operations
$
67.6
$
63.8
R&D Expense – Discontinued Operations
$
2.5
$
29.9
SG&A Expense – Continuing Operations
$
179.7
$
167.8
SG&A Expense – Discontinued Operations
$
–
$
6.6
Year-over-year increase in R&D expense related to continuing operations was driven primarily by investment in the ALKS 2680 development program and approximately $3.2 million of non-recurring share-based compensation expenses.
Year-over-year increase in SG&A expense related to continuing operations was driven primarily by investment in the LYBALVI direct-to-consumer advertising campaign and approximately $6.2 million of non-recurring share-based compensation expenses.
Balance Sheet
At March 31, 2024, the company recorded cash, cash equivalents and total investments of $807.8 million, compared to $813.4 million at Dec. 31, 2023. The company’s total debt outstanding as of March 31, 2024 was $290.1 million.
Financial Expectations for 2024
Alkermes reiterates its financial expectations for 2024, as set forth in its press release dated Feb. 15, 2024.
Recent Events
In March 2024, the company announced the appointment of new independent director Nancy S. Lurker to the company’s board of directors.
In April 2024, the company presented data from its long-term safety study of LYBALVI (olanzapine and samidorphan) at the 2024 Congress of the Schizophrenia International Research Society (SIRS).
In April 2024, the company announced positive topline results from the narcolepsy type 2 and idiopathic hypersomnia cohorts in its phase 1b study of ALKS 2680, the company’s novel, investigational orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy.
In April 2024, the company announced initiation of the Vibrance-1 phase 2 study of ALKS 2680 in patients with narcolepsy type 1.
Notes and Explanations
1. The company determined that upon the separation of its oncology business, completed on Nov. 15, 2023, the oncology business met the criteria for discontinued operations in accordance with Financial Accounting Standards Board Accounting Standards Codification 205, Discontinued Operations. Accordingly, the accompanying selected financial information has been updated to present the results of the oncology business as discontinued operations for the three months ended March 31, 2023.
Conference Call
Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes’ website.